Florian Foeger
Founder & Chief Executive Officer CYPRUMED
Florian Föger is the founder of Cyprumed GmbH and the inventor of its next generation drug delivery technology. Previously, Florian Föger was Director of Oral Formulation Research at Novo Nordisk A/S in Denmark. He is the inventor of more than 10 patent applications in the field of oral peptide delivery and author of 17 peer reviewed research articles in the oral delivery field. Florian Föger received a PhD in Pharmaceutical Sciences from the University of Innsbruck, Austria.
Seminars
How close are we to making oral peptide therapeutics the new standard of care?
As demand grows for more convenient, patient-friendly therapies, how can developers overcome the persistent challenges of poor bioavailability, gastrointestinal degradation and limited permeability without compromising safety or scalability? Is it time to move beyond traditional permeation enhancers towards intrinsically orally available peptides? And which formulation strategies are best positioned to deliver clinically meaningful improvements while supporting successful translation to the clinic?
In this workshop:
- Discover how to increase peptide bioavailability from single digits to 20-30% by modifying physical properties rather than relying on traditional permeation enhancers
- Learn formulation strategies that enable scalable, cost-efficient oral delivery with favourable regulatory safety profiles
- Understand how double-digit bioavailability can be achieved with oral formulations entirely based on FDA approved excipients and peptide design
- Gain insights into selecting the right formulation technology early in preclinical development to avoid costly late-stage failures
- Master the critical transition from injectable to oral modalities to capture multi billiondollar market opportunities.
- When to engage formulation scientists in the discovery process to avoid late-stage failures.
- How to balance peptide design optimisation with formulation technology requirements.
- Real-world examples of peptide programs that succeeded or failed based on early formulation integration.
- Best practices for cross-functional collaboration between medicinal chemists and formulation scientists.
- Compare emerging in vitro models for assessing macrocyclic peptide permeability and identify the assays that deliver the greatest predictive value for in vivo outcomes.
- Explore how formulation and screening strategies can be integrated to strengthen translational decision-making from early discovery through preclinical development.
- Learn best practices for selecting predictive screening platforms that improve candidate quality, reduce development risk, and accelerate oral peptide programmes.
